QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
NASDAQ:RPRX

Royalty Pharma - RPRX Stock Forecast, Price & News

$44.35
+0.42 (+0.96%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$43.76
$44.56
50-Day Range
$38.20
$44.35
52-Week Range
$34.86
$44.75
Volume
2.00 million shs
Average Volume
1.99 million shs
Market Capitalization
$26.93 billion
P/E Ratio
57.60
Dividend Yield
1.73%
Price Target
$53.43

Royalty Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
20.5% Upside
$53.43 Price Target
Short Interest
Bearish
3.70% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.64
Upright™ Environmental Score
News Sentiment
-0.08mentions of Royalty Pharma in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$24.75 M Sold Last Quarter
Proj. Earnings Growth
20.07%
From $2.99 to $3.59 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Finance Sector

218th out of 924 stocks

Pharmaceutical Preparations Industry

32nd out of 555 stocks

RPRX stock logo

About Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma Stock Up 0.1 %

Royalty Pharma stock traded up $0.03 during mid-day trading on Tuesday, hitting $43.96. The company had a trading volume of 34,106 shares, compared to its average volume of 1,902,796. The company has a current ratio of 19.22, a quick ratio of 19.22 and a debt-to-equity ratio of 0.68. The stock's 50 day moving average price is $42.23 and its two-hundred day moving average price is $40.89. Royalty Pharma has a 12 month low of $34.86 and a 12 month high of $44.75. The company has a market capitalization of $26.69 billion, a PE ratio of 57.05, a price-to-earnings-growth ratio of 1.18 and a beta of 0.28.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 15th. Stockholders of record on Friday, August 19th will be issued a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.73%. The ex-dividend date of this dividend is Thursday, August 18th. Royalty Pharma's payout ratio is currently 98.70%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. The Goldman Sachs Group assumed coverage on Royalty Pharma in a research note on Wednesday, April 27th. They set a "buy" rating and a $56.00 target price on the stock. Scotiabank began coverage on Royalty Pharma in a research note on Friday, May 13th. They issued an "outperform" rating and a $53.00 price target on the stock. UBS Group began coverage on Royalty Pharma in a research note on Monday, June 13th. They issued a "buy" rating and a $47.00 price target on the stock. Tigress Financial upped their price target on Royalty Pharma from $52.00 to $57.00 and gave the stock a "buy" rating in a research note on Thursday, July 14th. Finally, Morgan Stanley upped their price target on Royalty Pharma from $48.00 to $51.00 and gave the stock an "overweight" rating in a research note on Monday, August 8th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $53.43.

Insider Activity

In other news, Director Rory B. Riggs sold 26,304 shares of the company's stock in a transaction on Thursday, May 19th. The stock was sold at an average price of $40.09, for a total transaction of $1,054,527.36. Following the transaction, the director now directly owns 575,408 shares of the company's stock, valued at $23,068,106.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Rory B. Riggs sold 26,304 shares of the company's stock in a transaction on Thursday, May 19th. The stock was sold at an average price of $40.09, for a total transaction of $1,054,527.36. Following the transaction, the director now directly owns 575,408 shares of the company's stock, valued at $23,068,106.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Terrance P. Coyne sold 30,000 shares of the company's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $43.19, for a total value of $1,295,700.00. Following the transaction, the chief financial officer now directly owns 970,000 shares in the company, valued at $41,894,300. The disclosure for this sale can be found here. Insiders have sold a total of 572,267 shares of company stock valued at $23,823,859 over the last ninety days. 24.86% of the stock is currently owned by corporate insiders.

Receive RPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter.

RPRX Stock News Headlines

Bargain in Today's Market (SHOCKING)
This "World's Most Admired" company's stock would be a bargain at $50...Today it's just $2! Plus... a key May 12 announcement could send it ROCKETING skyward... Click Here Now (Before It's Too Late!) pixel
Jim Cramer Shares His Takes On First Solar, Royalty Pharma And More
Board Member Of Royalty Pharma Makes $1.97M Sale
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Royalty Pharma Reports Second Quarter 2022 Results
Royalty Pharma (RPRX) Scheduled to Post Earnings on Thursday
Royalty Pharma Declares Third Quarter 2022 Dividend
See More Headlines
Receive RPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter.

RPRX Company Calendar

Last Earnings
11/10/2021
Ex-Dividend for 6/15 Dividend
5/19/2022
Dividend Payable
6/15/2022
Today
8/16/2022
Ex-Dividend for 9/15 Dividend
8/18/2022
Dividend Payable
9/15/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Finance
Current Symbol
NASDAQ:RPRX
CUSIP
76028H20
Fax
N/A
Employees
51
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$53.43
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$47.00
Forecasted Upside/Downside
+20.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$619.73 million
Pretax Margin
39.61%

Debt

Sales & Book Value

Annual Sales
$2.29 billion
Cash Flow
$2.99 per share
Book Value
$16.88 per share

Miscellaneous

Free Float
456,265,000
Market Cap
$26.93 billion
Optionable
Not Optionable
Beta
0.28

Social Links


Key Executives

  • Mr. Pablo Gerardo Legorreta (Age 58)
    Founder, Chairman & CEO
    Comp: $49.51M
  • Mr. Terrance P. Coyne
    Exec. VP & CFO
  • Mr. George Wingate Lloyd (Age 63)
    Exec. VP of Investments & Gen. Counsel
    Comp: $3.9M
  • Mr. Christopher Hite (Age 54)
    Vice Chairman & Exec. VP
    Comp: $4.01M
  • Dr. Marshall Urist M.D.
    Ph.D., Exec. VP and Head of Research & Investments
  • Ms. Kristin Stafford
    Sr. VP & Chief Accounting Officer
  • Dr. James Folmar Reddoch Ph.D. (Age 52)
    Exec. VP of Investments & Chief Scientific Officer
  • Mr. George Grofik C.F.A.
    CPA, Sr. VP and Head of Investor Relations & Communications
  • Ms. Alessandra Sassun
    Head of Human Capital
  • Mr. Sandy Balkin Ph.D.
    Sr. VP of Strategy & Analytics













RPRX Stock - Frequently Asked Questions

Should I buy or sell Royalty Pharma stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RPRX shares.
View RPRX analyst ratings
or view top-rated stocks.

What is Royalty Pharma's stock price forecast for 2022?

7 equities research analysts have issued 1-year price objectives for Royalty Pharma's shares. Their RPRX share price forecasts range from $47.00 to $60.00. On average, they expect the company's stock price to reach $53.43 in the next twelve months. This suggests a possible upside of 20.5% from the stock's current price.
View analysts price targets for RPRX
or view top-rated stocks among Wall Street analysts.

How have RPRX shares performed in 2022?

Royalty Pharma's stock was trading at $39.85 at the beginning of 2022. Since then, RPRX shares have increased by 11.3% and is now trading at $44.35.
View the best growth stocks for 2022 here
.

When is Royalty Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our RPRX earnings forecast
.

How were Royalty Pharma's earnings last quarter?

Royalty Pharma plc (NASDAQ:RPRX) issued its quarterly earnings data on Wednesday, November, 10th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.69 by $0.52. The biopharmaceutical company earned $587 million during the quarter, compared to the consensus estimate of $568.92 million. Royalty Pharma had a trailing twelve-month return on equity of 17.27% and a net margin of 20.66%. During the same quarter last year, the company earned $0.48 EPS.

How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma?

Royalty Pharma announced a quarterly dividend on Monday, July 18th. Investors of record on Friday, August 19th will be given a dividend of $0.19 per share on Thursday, September 15th. This represents a $0.76 annualized dividend and a dividend yield of 1.71%. The ex-dividend date is Thursday, August 18th.
Read our dividend analysis for RPRX
.

Is Royalty Pharma a good dividend stock?

Royalty Pharma (NASDAQ:RPRX) pays an annual dividend of $0.76 per share and currently has a dividend yield of 1.73%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 98.70%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, RPRX will have a dividend payout ratio of 21.17% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RPRX.

What other stocks do shareholders of Royalty Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), Salesforce (CRM) and Twilio (TWLO).

When did Royalty Pharma IPO?

(RPRX) raised $1.9 billion in an initial public offering (IPO) on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank acted as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers.

What is Royalty Pharma's stock symbol?

Royalty Pharma trades on the NASDAQ under the ticker symbol "RPRX."

Who are Royalty Pharma's major shareholders?

Royalty Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (5.92%), Baillie Gifford & Co. (2.96%), JPMorgan Chase & Co. (1.26%), State Street Corp (1.26%), abrdn plc (0.59%) and Northern Trust Corp (0.39%). Insiders that own company stock include Adage Capital Partners Gp, LL, George W Lloyd, Henry A Fernandez, James F Reddoch, James F Reddoch, Marshall Urist, Pablo G Legorreta, Rory B Riggs, Sanjay Kumar Singh, Scientific Corp Boston, Terrance P Coyne and William E Ford.
View institutional ownership trends
.

How do I buy shares of Royalty Pharma?

Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Royalty Pharma's stock price today?

One share of RPRX stock can currently be purchased for approximately $44.35.

How much money does Royalty Pharma make?

Royalty Pharma (NASDAQ:RPRX) has a market capitalization of $26.93 billion and generates $2.29 billion in revenue each year. The biopharmaceutical company earns $619.73 million in net income (profit) each year or $0.77 on an earnings per share basis.

When was Royalty Pharma founded?

Royalty Pharma was founded in 1996.

How can I contact Royalty Pharma?

Royalty Pharma's mailing address is 110 E 59th Street, New York NY, 10022. The official website for the company is www.royaltypharma.com. The biopharmaceutical company can be reached via phone at 212-883-0200 or via email at ir@royaltypharma.com.

This page (NASDAQ:RPRX) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.